Basso U et al. Older age limits the use of adjuvant chemotherapy according to all negative risk factors in early breast cancer patients. Proc ASCO 2004;Abstract 8159.

Berry DA et al. Effects of improvements in chemotherapy on disease-free and overall survival of estrogen-receptor negative, node-positive breast cancer: 20-year experience of the CALGB and U.S. Breast Intergroup. Breast Cancer Res Treat 2004;Abstract 29.

Bonadonna G et al. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and fluorouracil in operable breast cancer. J Clin Oncol 2004;22(9):1614-20. Abstract

Bonneterre J et al. Long-term cardiac followup in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J Clin Oncol 2004;22(15):3070-9. Abstract

Brain EGC et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high-risk node negative (pN0) and limited node positive (pN+≤3) breast cancer (BC) patients (pts): First analysis of toxicity. Proc ASCO 2004;Abstract 617.

Chan A et al. Adherence to clinical practice guidelines for adjuvant therapy of breast cancer. Proc ASCO 2004;Abstract 716.

Citron ML et al. Randomized trial of dosedense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract

Dang CT et al. Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. Clin Cancer Res 2004;10(17):5754- 61. Abstract

Delozier T et al. Reducing dose density in adjuvant chemotherapy (C) is detrimental in early breast cancer (EBC). A review of 872 adjuvant treatments in Centre François Baclesse. Proc ASCO 2004;Abstract 583.

Duric V et al. Predictors of the benefits women consider necessary to make adjuvant chemotherapy (ACT) worthwhile for early breast cancer (EBC). Proc ASCO 2004;Abstract 787.

Elling D et al. Adjuvant treatment of breast cancer patients with 1-3 positive lymph nodes: vinorelbine plus epirubicin; vinorelbine plus epirubicin sequential followed up by paclitaxel; epirubicin plus cyclophosphamide; epirubicin plus cyclophosphamide sequential followed up by paclitaxel. A phase II study. Breast 2003;12(3):208-11. Abstract

Fumoleau P et al. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 2003;21(2):298-305. Abstract

Ghani F et al. Confirmation of C9741 intergroup results in a prospectively randomized trial comparing dose-intense chemotherapy with G-CSF support to 3-weekly chemotherapy for adjuvant therapy of nodal-positive (1-3 LN) breast cancer: Longitudinal CA 27.29 results indicate higher decay of minimal residual disease in the dosedense arm. Proc ASCO 2004;Abstract 805.

Guida M et al. Impairment of cognitive function in patients submitted to adjuvant chemotherapy for early breast cancer: A follow up study. Proc ASCO 2004;Abstract 8027.

Henderson IC et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21(6):976-83. Abstract

Lambert-Falls R et al. A phase II study to evaluate the feasibility of bi-weekly docetaxel followed by bi-weekly doxorubicin and cyclophosphamide as adjuvant therapy for operable breast cancer (T-AC). Proc ASCO 2004;Abstract 850.

Lara R et al. Feasibility of adjuvant chemotherapy with doxorubicin plus docetaxel followed by sequential capecitabine in patients with node positive breast cancer. Proc ASCO 2004;Abstract 782.

Loesch D et al. A randomized, multicenter phase III trial comparing regimens of doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for patients with high risk breast cancer. Breast Cancer Res Treat 2004;Abstract 28.

Martin M et al. Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for nodenegative breast cancer (BC): An interim safety analysis of the GEICAM 9805 study. Proc ASCO 2004;Abstract 620.

Martin M et al. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. Breast Cancer Res Treat 2003;Abstract 43.

Mintzer DM et al. Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: The effect of taxanes. Proc ASCO 2004;Abstract 687.

Olivotto IA et al. An independent population- based validation of the adjuvant decision- aid for stage I-II breast cancer. Proc ASCO 2004;Abstract 522.

Pacuicci PA et al. Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer. Anti- Cancer Drugs 2002;13(8):791-5. Abstract

Rea DW et al. Tolerability and efficacy of classical CMF (cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamide (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT). Proc ASCO 2004;Abstract 595.

Rizel S et al. Doxorubicin 75mg/m2 followed by cyclophosphamide, methotrexate, and fluorouracil (A ‡ CMF) in the adjuvant treatment of node positive breast cancer: Outcome and toxicity in 136 patients. Proc ASCO 2004;Abstract 849.

Rodenhuis S et al; Netherlands Working Party on Autologous Transplantation in Solid Tumors. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003;349(1):7-16. Abstract

Rodriguez-Lescure A et al. Multicenter, randomized phase III study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles (cy) of FEC vs 4 cy of FEC followed by 8 weekly paclitaxel (T) administrations: Safety analysis of GEICAM 9906 trial. Proc ASCO 2004;Abstract 596.

Ruzich M et al. A prospective evaluation of cognitive function in patients with early breast cancer receiving adjuvant chemotherapy. Proc ASCO 2004;Abstract 549.

Schott A et al. Adjuvant chemotherapy for elderly women with hormone receptor-positive breast cancer: an old(er) problem. J Clin Oncol 2004;22(23):Epub ahead of print. Abstract

Smith RE et al. Phase II trial of doxorubicin/ docetaxel doublet for locally advanced and metastatic breast cancer: results from national surgical adjuvant breast and bowel project trial BP-57. Clin Breast Cancer 2004;5(3):208-15. Abstract

Stricker CT et al. Anemia and fatigue during adjuvant chemotherapy for breast cancer: Patterns and impact on quality of life. Proc ASCO 2004;Abstract 8060.

Tallman MS et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in highrisk breast cancer. N Engl J Med 2003;349(1):17- 26. Abstract

Tchen N et al. Cognitive function, fatigue and menopausal symptoms in women following adjuvant chemotherapy for breast cancer: One and two year follow-up of a prospective controlled study. Proc ASCO 2004;Abstract 8001.

Thomas E et al. The use of alternate, non-crossresistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin- based regimen in women with operable breast cancer: Long-term results from a prospective randomized trial. J Clin Oncol 2004;22(12):2294- 302. Abstract

Tinker A et al. Impact of reduced dose intensity of adjuvant anthracycline based chemotherapy in a population based cohort of stage I-II breast cancers. Proc ASCO 2004;Abstract 552.

Vogel CL et al. The role of growth factor support following neutropenic events in early stage breast cancer (BC) patients treated with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC): A sub-analysis of BCIRG 001. Proc ASCO 2004;Abstract 677.

Zander AR et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial. J Clin Oncol. 2004;15;22(12):2273-83. Abstract